<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01995552</url>
  </required_header>
  <id_info>
    <org_study_id>Version 3.0 , 22 Apr 2015</org_study_id>
    <secondary_id>REF/2013/10/005823</secondary_id>
    <nct_id>NCT01995552</nct_id>
  </id_info>
  <brief_title>IdeNtifying High riSk Patients Post Myocardial Infarction With REduced Left Ventricular Function Using External Loop Recorders (INSPIRE-ELR Study)</brief_title>
  <acronym>INSPIRE-ELR</acronym>
  <official_title>IdeNtifying High riSk Patients Post Myocardial Infarction With REduced Left Ventricular Function Using External Loop Recorders (INSPIRE-ELR Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic BRC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medtronic BRC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the INSPIRE-ELR study is to characterize arrhythmias in post MI low EF (≤35%)
      patients in the acute phase (at discharge from hospital after index MI) and chronic phase (at
      8-10 weeks after index MI) and to correlate with patients at high risk of all-cause mortality
      or sudden cardiac death (SCD) at 1 year.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a prospective, multi-center, interventional, non-randomized study enrolling post
      MI low left ventricular ejection fraction (LVEF ≤35%) patients prior to or at discharge from
      the hospital after index MI as defined in the inclusion criteria. Prior to initiating any
      study specific procedures, patients needs to provide his/her consent by signing and dating an
      informed consent form. Inclusion/Exclusion criteria will be evaluated and the patients'
      medical history and baseline information will be collected. Seven days ELR monitoring will be
      done at discharge and at chronic phase after index MI. At 6 and 9 months telephone follow-up
      will be done to evaluate the health status, if there will be no in-office visit planned. At
      12 months there will be a scheduled in-office visit conducted to collect the health status.
      All the patients will be followed-up by telephone (health status) at study end (when the last
      patient completed the 12 month follow-up)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2014</start_date>
  <completion_date type="Actual">April 2017</completion_date>
  <primary_completion_date type="Actual">February 20, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Primary Objective of the Study is to Assess Percent of Participants With Clinically Significant Arrhythmias on ELR Post MI</measure>
    <time_frame>7 days post discharge</time_frame>
    <description>Post MI mortality is higher in India than in the US and Western Europe. The hypothesis of the INSPIRE-ELR study was that occurrence of arrhythmias in the acute phase of MI will identify patients at highest risk and we evaluated the percentage clinical signification arrhythmias captured through the ELR post MI in acute phase</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine Percentage of Patients With Non-lethal Arrhythmias on ELR Post MI Have a Higher Risk of All-cause Mortality at 1 Year</measure>
    <time_frame>12 Months</time_frame>
    <description>Analysis included all patients that completed the acute monitoring period. Based on the arrhythmias detected during the acute ELR monitoring period, patients were classified as &quot;with arrhythmia&quot; when during the ELR monitoring period there is any episode of ELR monitored events listed. All other patients are classified &quot;without arrhythmia&quot;. Mortality rates after the monitoring period was estimated for both groups.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">250</enrollment>
  <condition>Post MI Left Ventricular Dysfunction</condition>
  <arm_group>
    <arm_group_label>External Loop Recorder</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>This is a non-randomized study. All the patients will be enrolled will received the ELR system.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>External Loop Recorder</intervention_name>
    <arm_group_label>External Loop Recorder</arm_group_label>
    <other_name>NUVANT Mobile Cardiac Telemetry (MCT) system (CorventisTM)</other_name>
    <other_name>SEEQ™ External Cardiac Monitor (ECM) system (Medtronic, Inc., Minneapolis, MN)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Patients must meet all of the below criteria to be eligible for the study:

          -  Patients must provide written informed consent/data release consent to

          -  participate in the study.

          -  Acute Myocardial Infarction (STEMI or non-STEMI) documented within 10 days of onset,
             matching one of the following criteria:

          -  Acute ST segment elevation greater than or equal to 0.1 mv on ECG in 2 or more leads
             or new LBBB, with symptoms of ischemia

          -  In all other situations, including non ST segment elevation MI, at least one cardiac
             biomarker value [preferably cardiac troponin (cTn)] above the 99th percentile of a
             normal reference population (upper reference limit (URL)) AND with at least one of the
             following (1) new or presumed new ST-T changes (2) Symptoms or signs of Ischemia (3)
             Development of pathological Q waves in the ECG (4) Identification of an intracoronary
             thrombus by angiography

          -  LVEF less than or equal to 35 percent as measured by echocardiography Simpsons method,
             biplane one day before or on the day of hospital discharge

        Exclusion Criteria

          -  Patients who cannot be discharged from the hospital within14 days after index
             Myocardial Infarction event

          -  Age less than 18 years

          -  Psychologically incapacitated

          -  Patient is pregnant, or is expecting to become pregnant during the course of the trial
             per Investigator discretion.

          -  Patients contraindicated for NUVANT system

          -  Comorbidities likely to limit survival to less than the minimal study duration (12
             months)

          -  Participation in an investigational study with known or suspected cardiac effect
             expected to confound the results of this study (e.g. stem cell trials, stent trials,
             cardiac intervention trials, drug trials)

          -  Patients with an existing pacemaker or ICD implanted.

          -  Patients that are dialysis dependent at discharge
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medanta - The Medicity</name>
      <address>
        <city>Gurgaon</city>
        <state>Haryana</state>
        <zip>122001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>November 21, 2013</study_first_submitted>
  <study_first_submitted_qc>November 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 26, 2013</study_first_posted>
  <results_first_submitted>August 17, 2018</results_first_submitted>
  <results_first_submitted_qc>August 19, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 20, 2019</results_first_posted>
  <last_update_submitted>August 19, 2019</last_update_submitted>
  <last_update_submitted_qc>August 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Post myocardial infarction patients with low EF.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Ventricular Dysfunction</mesh_term>
    <mesh_term>Ventricular Dysfunction, Left</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study enrolled acute post MI patients with a reduced LVEF (≤35%) one day before or on the day of discharge from hospital after index MI. There is no control group in this study. The study was conducted in India and in multi specialty hospitals</recruitment_details>
      <pre_assignment_details>The first patient was enrolled on April 29, 2014. Enrollment continued until the 250th patient was enrolled on January 31, 2016. out of 250, patients, there were 233 patients in the analysis cohort, with at least 72 hours of monitoring documented in the ELR device data or a clinically significant arrhythmia in the first 72 hours of monitoring.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>External Loop Recorder (Single Arm)</title>
          <description>This is a non-randomized study. All the patients who were enrolled received the ELR system. (External Loop Recorder) After enrollment in the study the following visits are scheduled:
Baseline (day of discharge or one day before discharge after index MI). the main activities were Patient demographics, apply ELR, 12 lead ECG, LVEF etc.
Chronic phase follow-up visit: apply ELR, 12 lead ECG, LVEF etc. 6 and 9 months follow-up: Telephonic health status if patient is not seen.
12-month follow-up visit: In office visit, health status questionnaire
Extended follow-up beyond 12 months: Telephonic health status at the study end (when the last patient completes the 12 months follow up).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="250">There were 249 patients were included for Baseline cohort and 233 in analysis cohort</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="233">There were 233 patients who were eligible for primary objective analysis</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The baseline cohort consists of 250 patients and the analysis cohort of 233. There were 17 patients excluded from the analysis because they were not fulfilling the required criteria of analysis as per the protocol.</population>
      <group_list>
        <group group_id="B1">
          <title>External Loop Recorder (Single Arm)</title>
          <description>This is a non-randomized study. All the patients who were enrolled received the ELR system. (External Loop Recorder)
After enrollment in the study the following visits are scheduled:
Baseline (day of discharge or one day before discharge after index MI). the main activities were Patient demographics, apply ELR, 12 lead ECG, LVEF etc.
Chronic phase follow-up visit: apply ELR, 12 lead ECG, LVEF etc. 6 and 9 months follow-up: Telephonic health status if patient is not seen.
12-month follow-up visit: In office visit, health status questionnaire
Extended follow-up beyond 12 months: Telephonic health status at the study end (when the last patient completes the 12 months follow up).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="250"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>1 patient was excluded due to LVEF &gt;35% which is the exclusion criteria</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="249"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="192"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="250"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>one patient was excluded due to LVEF&gt;35 which is the exclusion criteria</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="249"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>India</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="250"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ejection Fraction</title>
          <population>The baseline cohort consists of 249 patients and the analysis cohort of 233.</population>
          <units>% Ejection Fraction</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="249"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.7" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Primary Objective of the Study is to Assess Percent of Participants With Clinically Significant Arrhythmias on ELR Post MI</title>
        <description>Post MI mortality is higher in India than in the US and Western Europe. The hypothesis of the INSPIRE-ELR study was that occurrence of arrhythmias in the acute phase of MI will identify patients at highest risk and we evaluated the percentage clinical signification arrhythmias captured through the ELR post MI in acute phase</description>
        <time_frame>7 days post discharge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>External Loop Recorder (Single Arm)</title>
            <description>This is a non-randomized study. All the patients will be enrolled will received the ELR system.</description>
          </group>
        </group_list>
        <measure>
          <title>The Primary Objective of the Study is to Assess Percent of Participants With Clinically Significant Arrhythmias on ELR Post MI</title>
          <description>Post MI mortality is higher in India than in the US and Western Europe. The hypothesis of the INSPIRE-ELR study was that occurrence of arrhythmias in the acute phase of MI will identify patients at highest risk and we evaluated the percentage clinical signification arrhythmias captured through the ELR post MI in acute phase</description>
          <units>percentage of analyzed population</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="233"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.5" lower_limit="42.2" upper_limit="54.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Determine Percentage of Patients With Non-lethal Arrhythmias on ELR Post MI Have a Higher Risk of All-cause Mortality at 1 Year</title>
        <description>Analysis included all patients that completed the acute monitoring period. Based on the arrhythmias detected during the acute ELR monitoring period, patients were classified as &quot;with arrhythmia&quot; when during the ELR monitoring period there is any episode of ELR monitored events listed. All other patients are classified &quot;without arrhythmia&quot;. Mortality rates after the monitoring period was estimated for both groups.</description>
        <time_frame>12 Months</time_frame>
        <population>There were total 28 deaths reported</population>
        <group_list>
          <group group_id="O1">
            <title>Acute Phase (With Arrhythmias)</title>
            <description>Patients were classified as “with significant arrhythmia” when during the ELR monitoring period and mortality was seen during 12 month follow-up.</description>
          </group>
          <group group_id="O2">
            <title>Acute Phase (Without Arrhythmias)</title>
            <description>Patients were classified as “without significant arrhythmia” when during the ELR monitoring period and mortality was seen during 12 month follow-up.</description>
          </group>
        </group_list>
        <measure>
          <title>Determine Percentage of Patients With Non-lethal Arrhythmias on ELR Post MI Have a Higher Risk of All-cause Mortality at 1 Year</title>
          <description>Analysis included all patients that completed the acute monitoring period. Based on the arrhythmias detected during the acute ELR monitoring period, patients were classified as &quot;with arrhythmia&quot; when during the ELR monitoring period there is any episode of ELR monitored events listed. All other patients are classified &quot;without arrhythmia&quot;. Mortality rates after the monitoring period was estimated for both groups.</description>
          <population>There were total 28 deaths reported</population>
          <units>percentage of Mortality</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.6" lower_limit="13.3" upper_limit="28.2"/>
                    <measurement group_id="O2" value="3.5" lower_limit="1.3" upper_limit="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All safety events were collected once the enrollment started and till the end of patient follow-ups during the period of 3 years</time_frame>
      <desc>As per the study protocol Deaths and Cardiovascular Related Serious Adverse Events were collected</desc>
      <group_list>
        <group group_id="E1">
          <title>External Loop Recorder (Single Arm)</title>
          <description>For this study, only Deaths and Cardiovascular Related Serious Adverse Events were collected. There were in total 28 deaths and 49 SAEs reported. No system or procedure related SAE were reported</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="249"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="249"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <description>Cardiac arrest</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="249"/>
              </event>
              <event>
                <sub_title>Acute left ventricular failure</sub_title>
                <description>Acute left ventricular failure</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="249"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <description>Cardiac failure congestive</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="249"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <description>Coronary artery disease</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="249"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <description>Acute myocardial infarction</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="249"/>
              </event>
              <event>
                <sub_title>Ventricular tachyarrhythmia</sub_title>
                <description>Ventricular tachyarrhythmia</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="249"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <description>Ventricular tachycardia</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="249"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <description>Angina pectoris</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <description>Angina unstable</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <description>Atrial fibrillation</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <description>Atrioventricular block complete</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <description>Cardiac failure</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <description>Cardiac failure acute</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <description>Left ventricular dysfunction</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <description>Left ventricular failure</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>Death</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="249"/>
              </event>
              <event>
                <sub_title>Unevaluable event</sub_title>
                <description>Unevaluable event</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="249"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <description>Chest discomfort</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <description>Multi-organ failure</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <description>Sudden cardiac death</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
              </event>
              <event>
                <sub_title>Vascular stent restenosis</sub_title>
                <description>Vascular stent restenosis</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <description>Cerebral infarction</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
              </event>
              <event>
                <sub_title>Cerebrovascular disorder</sub_title>
                <description>Cerebrovascular disorder</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <description>Dyspnoea</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="249"/>
              </event>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <description>Acute pulmonary oedema</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <description>Dyspnoea exertional</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <description>Hypoxia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <description>Aortic stenosis</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="249"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Vinay Rajan Ph.D</name_or_title>
      <organization>India Medtronic Pvt. Ltd.</organization>
      <phone>+91 22.3307.4700</phone>
      <email>vinay.rajan@medtronic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

